Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia - Wikidata - wikimedia - TriplyDB

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q28261949

about

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia CD23/FcεRII: molecular multi-tasking The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Activation-induced cytidine deaminase (AID)-associated multigene signature to assess impact of AID in etiology of diseases with inflammatory component.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relap The spectrum of use of rituximab in chronic lymphocytic leukemia In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.Targeted treatment for chronic lymphocytic leukemia.Human schistosome infection and allergic sensitisation.Therapeutic advancement of chronic lymphocytic leukemia.Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Chronic lymphocytic leukemia: putting new treatment options into perspective.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Refractory chronic lymphocytic leukemia--new therapeutic strategies.Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.Salvage therapy for relapsed chronic lymphocytic leukemia.Emerging antibody combinations in oncology.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future.Treatment of relapsed or refractory chronic lymphocytic leukemia.Rituximab for chronic lymphocytic leukemia.Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.CD30 as a therapeutic target for lymphoma.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Promising therapies for the treatment of chronic lymphocytic leukemia.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23.Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran.

P2860

Q24605471-709EB589-5249-49C3-A033-1410A1411EDF Q24617708-7D8FACFE-2B06-475B-9EA4-3D7BC46400A5 Q26744365-07D9157C-AE62-419A-8007-C4DF084B21CE Q28315285-F1C243ED-91F2-401E-A3C8-D9F284361A73 Q31033615-F41B75C0-0F69-4C0E-BD62-279299FF1286 Q33406478-0BADA2B1-42C2-4DC8-AEC1-6540FF8A890A Q34044904-73228C5D-E58C-44E6-A238-E0A2210F6937 Q34310845-86FB37D0-4B91-4EB8-BDBA-A8FC270CB228 Q34433926-21F97956-0BD7-423D-BE79-65A2DE813896 Q34510030-9FAA2B67-E3BF-46A6-8A99-7D89FA8EBB0D Q35001579-C1E4478F-0728-499F-AEF5-34D005FC460C Q35599741-114FDD1F-5673-441B-B8FB-006CF63268F3 Q36210573-6CDCE494-2BE2-459D-BA00-8219F7503A4B Q36300303-924B8AB1-6282-4A47-AF77-09A752BD3D74 Q36612602-D6404F56-2A0C-454F-B014-F21E1912EE43 Q36979140-F5F9B96D-9BBD-44DD-AB03-0C5495E2C804 Q37734199-90A58674-ACFC-4B7B-A540-B5B6EE791D7F Q37767703-9CA68691-4252-4C9E-8B9E-0BDD01644B89 Q37786616-0AA2307C-1709-48A6-9A7F-A6CD38E72B4A Q37799820-18D628D9-42F6-4F2B-9357-A61E66CC93D4 Q37840932-DAD3ADA1-3AB0-4B62-BBAD-A53566F10678 Q37842484-A91784EE-B12B-4A0D-9BB6-A90D571936A7 Q37845824-2F90E0CF-D4FA-408B-BAB3-B5D51069F9DE Q37865547-6F1ABEDC-0134-437A-8F84-C9E0072D783B Q37893414-ED49A6F7-03A3-416D-9987-710A2E71F517 Q37913356-2B53121A-FD3C-4FF6-A2D0-2569BA1B3F0C Q37937083-C500C635-0277-4B03-85FB-F5BCFBC3D1AB Q37964916-41F17FE6-0A76-401F-9B2F-81F042F2C107 Q37988562-0E70358C-0C76-47E7-8556-6607891EAC2B Q38007853-ECB190DC-9CDA-4429-9587-0DD4B1DB1A71 Q38068494-F64DF9CB-7EDA-4E56-A96B-387F2C449328 Q38068932-B5419B81-19A8-4FD0-A28F-4FFFE92ED63C Q38126946-77A1B577-D39E-4995-B3DD-A07CEC95F459 Q38138482-D5D25AF4-3549-41BB-A1D1-6266CA7973FB Q38155343-B9BB8B31-E4BA-4887-A2AB-D96288990953 Q38366441-6AAF0125-1BC0-4D1A-982A-861F44F684E0 Q38445357-40D4F17C-3A8F-4B0C-A5BD-32064D16B4D1 Q38579129-00AF0610-4A51-4F3C-8FD0-F75F9B17B26C Q39393866-DD625AC3-62EA-4EA0-9A71-FA82AE5B9D26 Q39994604-C24752B7-0022-41DE-B82C-313F211D4339

P2860

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q28261949

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@ast

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@en

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@nl

type

label

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@ast

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@en

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@nl

prefLabel

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@ast

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@en

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@nl

P1433

Q28261949-56991091-A1F7-4C22-8699-55593EB4B58E

P1476

Q28261949-112A726E-3AF6-4C83-B393-2BA47B1B16FE

P2093

Q28261949-01032CCD-88B1-470F-B9F3-4A1119C28F78

Q28261949-2830E491-85F5-4ABD-988D-F6080ACC3F44

Q28261949-2FE482C1-E117-4DD4-844B-8EB90FAFE610

Q28261949-5B753FF6-74B5-4988-A34A-CA49A216F678

Q28261949-6564DD66-6501-4D31-ABB0-E47F7CAC2991

Q28261949-6926EFD4-0F44-4311-B796-961EF53BA654

Q28261949-907CF4BC-C6A6-4343-9B7F-9CC43DE0F570

Q28261949-A4094112-583E-486A-85A6-E36A485E6E60

Q28261949-AC6DD294-9183-43B6-BF51-AFEDF2F9234C

Q28261949-B25CA526-B8C3-4360-A311-C36E91F8671F

P2860

Q28261949-10FEFF74-274F-451E-9BD1-82587DF12D79

Q28261949-19A23FE7-4228-4D4D-8223-D0C1333702D5

Q28261949-2D2C67A8-21CE-456E-B4B6-0D6080E143B6

Q28261949-38FC93DF-39A7-46C7-8CBA-B4F59B11607A

Q28261949-3AD3D8A7-FFCB-4FF2-B35A-28153F07231D

Q28261949-4BC1EE48-E94A-42D1-B5F7-2B4084C5D6E7

Q28261949-4DE0F8C0-2246-4232-9135-99ED60540F07

Q28261949-4E15B861-0D8E-4272-932F-85CDAF570C0B

Q28261949-58CDFAB6-4035-4F20-9687-3B561261460E

Q28261949-864A47F5-372B-4A4C-8BE0-2785AE5ACA17

P304

Q28261949-6A2DB480-EBD1-4637-87C0-A18D228CD67A

P31

Q28261949-DE896D00-0676-4BE5-B0B6-460EE0DAF107

P3181

Q28261949-28199AB8-6FCA-4EAF-B740-82ED9EE24007

P356

Q28261949-9A36259B-5321-4BD5-8BCA-E37E9D97B453

P407

Q28261949-E49BB59F-CF48-484D-8BF7-CE66E71952DA

P433

Q28261949-1A950BB6-470A-4A7B-904C-51E8B76B961E

P478

Q28261949-FCEE8707-D533-46B2-988E-25CF7D1DB095

P50

Q28261949-39C8836F-7550-4FE4-A187-BF9AFD7246CE

Q28261949-54B578C3-40EE-4F52-85EF-FA197928C79E

Q28261949-6551A1F9-6559-4BB0-A4B2-7C9393A27CC6

Q28261949-D1A84721-EB4C-44BF-B16C-A60B3C483201

P577

Q28261949-D58C489D-1091-42C4-901D-3A6A474CE4C3

P5875

Q28261949-8B8A5179-5436-46A6-8A0A-D0956465048F

P698

Q28261949-8F6A116B-5816-4931-BD06-C0B71149AE94

P921

Q28261949-416DAB95-CCBE-4A98-9499-F164A6B355D8

Q28261949-90458D2D-6805-4361-869A-D5FF75BF86C4

Q28261949-E3DC7651-269C-4196-8856-E15108F64498

Q28261949-FD397A9D-3A0B-44D1-AC55-11200EC5DBB1

P932

Q28261949-02CB576F-26D0-46F0-AC81-7E92F0397F0E

P3181

P356

BLOOD-2009-08-237727

P1433

P1476

Phase 1/2 study of lumiliximab ...... y chronic lymphocytic leukemia

@en

P2093

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Bryan Leigh

http://www.w3.org/2001/XMLSchema#string

Dee Wynne

http://www.w3.org/2001/XMLSchema#string

Ian W Flinn

http://www.w3.org/2001/XMLSchema#string

James Woodworth

http://www.w3.org/2001/XMLSchema#string

Januaro Castro

http://www.w3.org/2001/XMLSchema#string

Sarah Harris

http://www.w3.org/2001/XMLSchema#string

Shabnam Tangri

http://www.w3.org/2001/XMLSchema#string

Steve Hughes

http://www.w3.org/2001/XMLSchema#string

Thomas J Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.

P304

489-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

659459

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2009-08-237727

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

William G Wierda

P577

2010-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38024861

http://www.w3.org/2001/XMLSchema#string

P698

19843887

http://www.w3.org/2001/XMLSchema#string

P921

P932

2810983

http://www.w3.org/2001/XMLSchema#string